Factor-Xa-Inhibitor

• Deep-Dive: Predictors of Hematoma Expansion and Response to Andexanet — ANNEXA-I Secondary Analyses

  August 20, 2026

  ANNEXA-I secondary analyses: andexanet benefit amplifies in highest-risk HE quartiles (NNT ~4) without amplifying thrombotic-event risk; authors propose an 11-to-1 rule.